These results suggest that ILC2 in NPs may be phenotypically altered compared to ILC2 in blood, tonsil and CRSsNP and also that ILC2 were already activated and releasing type 2 cytokines including IL‐5 and IL‐13 in NPs. The gene discussed is IL13; the disease is chronic rhinosinusitis without nasal polyps.